Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials

Area of Science:

• Microbiology
• Infectious Diseases
• Biotechnology

Background:

• Lower respiratory tract infections and tuberculosis cause millions of deaths annually, particularly in children.
• Streptococcus pneumoniae is a primary cause of severe pneumonia, with biofilms contributing to persistent infections.
• Multidrug resistance in bacterial pathogens necessitates novel therapeutic strategies.

Purpose of the Study:

• To review the efficacy of phage lysins as an alternative therapeutic approach against bacterial respiratory pathogens.
• To highlight the potential of lysins in overcoming antibiotic resistance and biofilm formation.
• To summarize current in vitro and in vivo findings on lysins targeting respiratory pathogens.

Main Methods:

• Literature review of in vitro and in vivo studies on phage lysins.
• Analysis of lysin mechanisms of action against bacterial peptidoglycan.
• Evaluation of strategies to enhance lysin activity against Gram-negative bacteria.

Main Results:

• Phage lysins demonstrate potent bactericidal activity against susceptible bacteria by degrading peptidoglycan.
• Lysins are well-tolerated, do not typically elicit adverse immune responses, and are unlikely to induce resistance.
• Recent strategies have shown promise in overcoming previous limitations of lysin efficacy against Gram-negative bacteria.

Conclusions:

• Phage lysins represent a viable and attractive alternative to conventional antibiotics for treating respiratory tract infections.
• Their unique mechanism of action and low resistance potential make them valuable against multidrug-resistant and biofilm-forming pathogens.
• Continued research and development of lysin-based therapies are crucial for combating the growing threat of bacterial infections.